Pharmacology and Chemical Biology Welomes Dr. Tyler Beyett
Pharmacology and Chemical Biology welcomes Dr. Tyler Beyett as an assistant professor. Dr. Beyett will start at Emory May 1, 2023. He will also be a member of the Winship Cancer Institute.
Dr. Beyett obtained his PhD in Chemical Biology from the Life Sciences Institute at the University of Michigan in the lab of Dr. John Tesmer, where he studied the structure and regulation of GPCR kinases. He was a Ruth L. Kirschstein postdoctoral fellow at the Dana-Farber Cancer Institute and Harvard Medical School with Dr. Michael Eck.
His lab will primarily focus on the discovery and development of small molecule therapeutics targeting kinases in cancer.
More News
Drs. Ray Dingledine and George Painter have been selected as 2022 Fellows of the National Academy of Inventors (NAI)
Drs. Ray Dingledine and George Painter are among 169 new fellows representing 110 research universities and government and non-profit research institutes worldwide. The 2022 fellow class collectively holds more than 5,000 U.S. government-issued patents.
“Each of these individuals have made significant impact through their work and are highly-regarded in their respective fields,” said Dr. Paul Sanberg, FNAI, President of the NAI. “The breadth and scope of their inventions is truly staggering. I am excited to see their creativity continue to define a new era of science and technology in the global innovation ecosystem.”
This year’s class of fellows will be inducted in June 2023 at NAI’s 12th anniversary meeting in Washington, DC.
Ray Dingledine
Ray Dingledine, PhD, is a professor in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine, a department he chaired for 25 years. He also served as Executive Associate Dean of Research in the School of Medicine for 11 years. He has co-authored more than 240 peer-reviewed papers and is co-inventor on ten awarded patents. Dingledine’s research over the past decade has focused on the consequences of inflammation in the brain. He and his colleagues have drawn on multiple disciplines (high throughput pharmacology, electrophysiology, immunology, molecular biology, behavior and medicinal chemistry) to create a suite of novel anti-inflammatory drugs that are potent, selective, brain permeant and orally available.
“I am so proud to be inducted into the same NAI class as George Painter, a member of our department who is a true giant in academic drug development,” Dingledine says. “The high throughput screening center I and colleagues created in 2003 has morphed into the Emory Chemical Biology Discovery Center, which has been instrumental in our success and that of many other laboratories at Emory.”
George Painter, PhD
George Painter, PhD, is Endowed George R Painter III Distinguished Professor, Department of Pharmacology and Chemical Biology of the Emory University School of Medicine, CEO of Drug Innovation Ventures at Emory, and Executive Director of the Emory Institute for Drug Development. With an extensive background in the discovery and development of pharmaceutical agents during stints at Burroughs Welcome, Triangle Pharmaceuticals and Chimerix Inc, Painter is a co-inventor of more than 45 patents, six of which have led to approved commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. Most recently, Painter received international acclaim for his life-saving work in developing molnupiravir, which is now approved globally for the treatment of COVID-19. Painter received his B.S., M.S. and PhD from Emory’s Department of Chemistry.
The National Academy of Inventors is a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with more than 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the United States Patent and Trademark Office (USPTO), enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate, and mentor innovative students, and translate the inventions of its members to benefit society. The NAI has a close partnership with the USPTO and is one of three honorific organizations, along with the National Medals and National Inventors Hall of Fame, working closely with the USPTO on many discovery and innovation support initiatives.
The NAI Fellows Program recognizes academic inventors who have created or facilitated inventions that have made a tangible impact on quality of life, economic development and the welfare of society. To date, NAI Fellows hold more than 58,000 issued U.S. patents, which have generated more than 13,000 licensed technologies and companies, and created more than one million jobs. NAI fellow status is the highest professional distinction awarded to academic inventors.
George Painter Honored by Emory President
Dr. George Painter, Endowed George R Painter III Distinguished Professor of Pharmacology and Chemical Biology, was honored by Emory president Gregory Fenves and Carmel Fenves at their Lullwater House. This celebration event was to “toast George and recognize his many accomplishments at Emory.”
Attendees included Dr. Painter's family, Pharmacology and Chemical Biology Chair Haian Fu, provost Ravi B, EVP Ravi T, Interim EVP David Stephens, and RIVE director Dennis Liotta. Also in attendance were Ridgeback’s Wendy Holmes (CEO) and Wayne Holmes, CMO Wendy Painter, among others.
Dr. Thota Ganesh Receives ASPET Scientific Achievement Award in Drug Discovery and Development
Dr. Thota Ganesh, Associate Professor of Pharmacology and Chemical Biology, received the 2023 Scientific Achievement Award in Drug Discovery and Development award. This award recognizes outstanding investigators that have made significant contributions in drug discovery, translational and/or drug development science.
Ray Dingledine Receives AMSPC Award in Pharmacology Research and Administration
Dr. Ray Dingledine, Professor of Pharmacology and Chemical Biology, received the AMSPC Award in Pharmacology Research and Administration from the Association of Medical School Pharmacology Chairs (AMSPC), 2023. Ray accepted the award plaque at the 2023 AMSPC annual meeting at the CasaMagna Marriott Puerto Vallarta Resort & Spa, Mexico.
Wan Lab Publishes Article in "Science Advances"
The lab of Dr. Yong Wan published an article titled, "Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity," in Science Advances, January 2023.
In this work, proteomic analysis together with an array of patient tissue cohort specimen identified that unexpected accumulation of CD73 protein expression, an immune checkpoint protein, is associated with a poor prognosis and suppressed anti-tumor immunity in triple negative breast cancer. This work for the first time identified that CD73 is regulated by posttranslational modifications whose dysregulated protein degradation disrupts anti-breast tumor immune response. The new evidence from this study highlights the importance of targeting CD73 and how its posttranslational modifiers could be a promising strategy to reprogram the tumor microenvironment and a potential therapeutic target in triple negative breast cancer treatment.
Eric Miller Leads Winship Research Team to Receive Inaugural Winship Catalyst Fund Award
A Winship research team, led by Eric Miller, PhD, Pharmacology and Chemical Biology Instructor, has been named the inaugural recipient of a Winship Catalyst Fund award for their project, “Best-in-class orally bioavailable small molecule CXCR4 antagonists for cancer treatment.” Provided through a generous philanthropic gift from Berry Gray, the Winship Catalyst Fund supports the development of novel approaches for cancer therapy, diagnostics, or prevention, with the goal of seeking an investigational new drug (IND) application from the FDA.
Congrats to Eric and team!!